DISHMAN PHARMACEUTICALS & CHEMICALS LTD. - (AMALGAMATED)

NSE : NABSE : 532526ISIN CODE : INE353G01020Industry : Pharmaceuticals & DrugsHouse : Dishman Pharma
BSE301.050 (0 %)
PREV CLOSE ( ) 301.05
OPEN PRICE ( ) 293.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 301.05 (1375)
VOLUME 460499
TODAY'S LOW / HIGH ( )278.10 304.30
52 WK LOW / HIGH ( ) 278.1304.3
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2016Mar2015Mar2014Mar2013Mar2012
Profit Before Tax2333.601592.001564.021452.84879.12
Adjustment1863.001609.402219.261556.80730.20
Changes In working Capital-834.80176.30-34.26-1167.4663.93
Cash Flow after changes in Working Capital3361.803377.703749.031842.181673.26
Cash Flow from Operating Activities2786.402936.903445.021651.421535.76
Cash Flow from Investing Activities-1528.90-1580.60-2567.98-1172.83-1040.01
Cash Flow from Financing Activities-941.00-1420.20-740.62-501.49-680.40
Net Cash Inflow / Outflow316.50-63.90136.43-22.90-184.65
Opening Cash & Cash Equivalents243.90307.80171.38194.28425.06
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANANA
Effect of Foreign Exchange FluctuationsNANANANANA
Closing Cash & Cash Equivalent560.40243.90307.81171.38240.41

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.